Helix BioPharma Corp Initiates Enrollment for 7th Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the seventh dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle …

Helix BioPharma Corp Initiates Enrollment for 6th Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the sixth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle …

Direct of Helix BioPharma Corp. Acquires a Further 1,000,000 Common Shares

Helix BioPharma Corp. (TSX , FSE : ” HBP” ), a biopharmaceutical company dedicated to developing drugs for prevention and treatment of cancer, today announced that it has been advised by Dr. Marek Orlowski, a member of the board of directors of Helix and Chairman of the Supervisory Board of Helix Polska, that he has purchased 1,000,000 previously issued and …

Helix Announces the Results of Its Annual General and Special Meeting

AURORA, ONTARIO–(Marketwired – Dec 18, 2013) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announces that its Annual General and Special Meeting (the “Meeting”) was held today as scheduled.

Helix BioPharma Announces Director Resignation

AURORA, ON–(Marketwired – Dec 17, 2013) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that Mario Gobbo has resigned from Helix’s board of directors.

Helix BioPharma Corp. Announces Fiscal Q1 2014 Results

AURORA, ON–(Marketwired – Dec 13, 2013) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced financial results for the three-month period ended October 31, 2013.

Helix BioPharma Corp. Announces Changes in Senior Management

AURORA, ON–(Marketwired – Dec 6, 2013) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has terminated its employment of John Docherty, effective immediately.

Helix BioPharma Corp. Announces Completion of Private Placement

Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has completed a private placement with net proceeds in excess of CDN$4.6 million, after fees and expenses associated with this transaction.

Helix BioPharma Corp. Annouces Fiscal 2013 Results

Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced financial results for the year ended July31, 2013.